FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177211148> ?p ?o ?g. }

• W3177211148 abstract "Evidence from single and multicenter phase II trials have suggested diffusion MRI is a predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF therapy. The current study confirms these findings in a large, randomized phase III clinical trial.Patients with rGBM were enrolled in a phase III randomized (1:1), controlled trial (NCT02511405) to compare the efficacy and safety of bevacizumab (BV) versus BV in combination with ofranergene obadenovec (BV+VB-111), an anti-cancer viral therapy. In 170 patients with diffusion MRI available, pretreatment enhancing tumor volume and ADC histogram analysis were used to phenotype patients as having high (>1.24 µm2/ms) or low (<1.24 µm2/ms) ADCL, the mean value of the lower peak of the ADC histogram, within the contrast enhancing tumor.Baseline tumor volume (P = .3460) and ADCL (P = .2143) did not differ between treatment arms. Univariate analysis showed patients with high ADCL had a significant survival advantage in all patients (P = .0006), as well as BV (P = .0159) and BV+VB-111 individually (P = .0262). Multivariable Cox regression accounting for treatment arm, age, baseline tumor volume, and ADCL identified continuous measures of tumor volume (P < .0001; HR = 1.0212) and ADCL phenotypes (P = .0012; HR = 0.5574) as independent predictors of OS.Baseline diffusion MRI and tumor volume are independent imaging biomarkers of OS in rGBM treated with BV or BV+VB-111." @default.
• W3177211148 created "2021-07-05" @default.
• W3177211148 creator A5021656597 @default.
• W3177211148 creator A5024208131 @default.
• W3177211148 creator A5025351354 @default.
• W3177211148 creator A5025978662 @default.
• W3177211148 creator A5034837880 @default.
• W3177211148 creator A5036347055 @default.
• W3177211148 creator A5041483225 @default.
• W3177211148 creator A5046942262 @default.
• W3177211148 creator A5058736850 @default.
• W3177211148 creator A5062486524 @default.
• W3177211148 creator A5063511816 @default.
• W3177211148 creator A5076701506 @default.
• W3177211148 creator A5079645349 @default.
• W3177211148 creator A5083922162 @default.
• W3177211148 creator A5084168615 @default.
• W3177211148 creator A5087128361 @default.
• W3177211148 creator A5090305344 @default.
• W3177211148 date "2021-01-01" @default.
• W3177211148 modified "2023-10-16" @default.
• W3177211148 title "Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma" @default.
• W3177211148 cites W1911361012 @default.
• W3177211148 cites W1991634879 @default.
• W3177211148 cites W2015598446 @default.
• W3177211148 cites W2035347098 @default.
• W3177211148 cites W2052415231 @default.
• W3177211148 cites W2057230156 @default.
• W3177211148 cites W2060619590 @default.
• W3177211148 cites W2084090206 @default.
• W3177211148 cites W2099059965 @default.
• W3177211148 cites W2109487755 @default.
• W3177211148 cites W2125828556 @default.
• W3177211148 cites W2132697290 @default.
• W3177211148 cites W2140704845 @default.
• W3177211148 cites W2150311952 @default.
• W3177211148 cites W2150676817 @default.
• W3177211148 cites W2152805952 @default.
• W3177211148 cites W2165772224 @default.
• W3177211148 cites W2330598934 @default.
• W3177211148 cites W2536552580 @default.
• W3177211148 cites W2719272910 @default.
• W3177211148 cites W2795436270 @default.
• W3177211148 cites W2796029155 @default.
• W3177211148 cites W2803742466 @default.
• W3177211148 cites W2891393461 @default.
• W3177211148 cites W2995532498 @default.
• W3177211148 cites W2995556690 @default.
• W3177211148 cites W3021360974 @default.
• W3177211148 cites W3025901966 @default.
• W3177211148 cites W3084027654 @default.
• W3177211148 cites W35143804 @default.
• W3177211148 doi "https://doi.org/10.1093/noajnl/vdab082" @default.
• W3177211148 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8350152" @default.
• W3177211148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34377989" @default.
• W3177211148 hasPublicationYear "2021" @default.
• W3177211148 type Work @default.
• W3177211148 sameAs 3177211148 @default.
• W3177211148 citedByCount "2" @default.
• W3177211148 countsByYear W31772111482022 @default.
• W3177211148 countsByYear W31772111482023 @default.
• W3177211148 crossrefType "journal-article" @default.
• W3177211148 hasAuthorship W3177211148A5021656597 @default.
• W3177211148 hasAuthorship W3177211148A5024208131 @default.
• W3177211148 hasAuthorship W3177211148A5025351354 @default.
• W3177211148 hasAuthorship W3177211148A5025978662 @default.
• W3177211148 hasAuthorship W3177211148A5034837880 @default.
• W3177211148 hasAuthorship W3177211148A5036347055 @default.
• W3177211148 hasAuthorship W3177211148A5041483225 @default.
• W3177211148 hasAuthorship W3177211148A5046942262 @default.
• W3177211148 hasAuthorship W3177211148A5058736850 @default.
• W3177211148 hasAuthorship W3177211148A5062486524 @default.
• W3177211148 hasAuthorship W3177211148A5063511816 @default.
• W3177211148 hasAuthorship W3177211148A5076701506 @default.
• W3177211148 hasAuthorship W3177211148A5079645349 @default.
• W3177211148 hasAuthorship W3177211148A5083922162 @default.
• W3177211148 hasAuthorship W3177211148A5084168615 @default.
• W3177211148 hasAuthorship W3177211148A5087128361 @default.
• W3177211148 hasAuthorship W3177211148A5090305344 @default.
• W3177211148 hasBestOaLocation W31772111481 @default.
• W3177211148 hasConcept C126322002 @default.
• W3177211148 hasConcept C126838900 @default.
• W3177211148 hasConcept C141341695 @default.
• W3177211148 hasConcept C143409427 @default.
• W3177211148 hasConcept C143998085 @default.
• W3177211148 hasConcept C149550507 @default.
• W3177211148 hasConcept C168563851 @default.
• W3177211148 hasConcept C185592680 @default.
• W3177211148 hasConcept C2776694085 @default.
• W3177211148 hasConcept C2777802072 @default.
• W3177211148 hasConcept C2781197716 @default.
• W3177211148 hasConcept C2989005 @default.
• W3177211148 hasConcept C45664433 @default.
• W3177211148 hasConcept C535046627 @default.
• W3177211148 hasConcept C55493867 @default.
• W3177211148 hasConcept C71924100 @default.
• W3177211148 hasConceptScore W3177211148C126322002 @default.
• W3177211148 hasConceptScore W3177211148C126838900 @default.
• W3177211148 hasConceptScore W3177211148C141341695 @default.
• W3177211148 hasConceptScore W3177211148C143409427 @default.

• next